In the paralytic disease botulism, the botulinum neurotoxin (BoNT) passes through the bloodstream to reach and inactivate neuromuscular junctions. Monoclonal antibodies (mAbs) may be useful BoNT countermeasures, as mAb combinations can rapidly clear BoNT from the blood circulation. We have previously shown that the BoNT-neutralizing potency of mAbs can be improved through red blood cell (RBC) immunoadherence. For example, a fusion protein (FP) that adheres biotinylated mAbs to the RBC surface enabled a pair of mAbs to neutralize 5000 LD50 BoNT/A in the mouse protection assay. Here, we added two mAbs to that combination, creating a 4-mAb:FP complex that neutralized 40,000 LD50 BoNT/A in vivo, and analyzed functional correlates of neutralization. The FP enhanced potency of BoNT/A immune complexes, providing the greatest magnitude of benefit to the 4-mAb combination. RBC binding of a BoNT/A complexed with 4-mAb:FP exhibited a bi-phasic clearance process in vivo. Most of the complexes were cleared within five minutes; the rest were cleared gradually over many hours. Peritoneal macrophages showed better uptake of the 4-mAb complex than the 3-mAb complex, and this was not affected by the presence of the FP. However, the addition of RBCs to the 4-mAb:FP BoNT/A doubled macrophage uptake of the complexes. Lastly, the 4-mAb:FP BoNT/A complex synergistically induced M2 macrophage polarization, as indicated by IL-10 expression, whether or not RBCs were present. RBC-targeted immunoadherence through the FP is a potent enhancer of mAb-mediated BoNT/A neutralization in vivo, and can have positive effects on BoNT/A sequestration, immune complex uptake, and macrophage activation.
Introduction
Despite widespread progress in antimicrobial drug development, emerging infectious diseases, drug-resistant pathogens, and toxin-producing pathogens remain a considerable global concern. Monoclonal antibodies (mAbs) have proven to be safe and effective as therapeutics for treating infectious diseases and toxins, yet their broad potential has been largely unrealized. This is partly because single mAbs have limited utility against pathogens that are antigenically diverse, have redundant mechanisms of virulence, or require oligomeric immune complex formation for clearance.
Results

Assembly of an Immune Complex with RBC Adherence and High-Potency BoNT/A Neutralization
In our previous study, we observed neutralization of 2000 LD50 with biotinylated 6A and 4LCA mAbs bound to the FP. We sought additional mAbs that would enable us to study the impact of higher-order complexes on RBC-dependent BoNT/A neutralization and clearance in vivo. Our goal was to create a multimeric FP-containing complex with neutralization potency comparable to the best results reported by others, i.e., 40,000 LD50 BoNT/A [4, 5] . We tested three BoNT/A heavy chain (HC)-specific mAbs for their ability to bind recombinant inactive BoNT/A (RI-BoNT/A) in the presence of the 6A and 4LCA mAbs. 3B3 is a human mAb that binds BoNT types A, B and E, but is not neutralizing; CR2 is a humanized mAb that neutralizes type BoNT/A in vivo with high potency; and 15A is a human mAb with modest BoNT/A neutralization activity [8] [9] [10] . We measured binding of biotinylated 6A to a BoNT/A dilution series in the presence or absence of the potential competitor mAbs (Figure 1) , and calculated the percentage of binding inhibition using the linear trapezoidal approximation method [11] . CR2 and 3B3 did not prevent 6A from binding to BoNT/A ( Figure 1A ,B), whereas 15A did compete with 6A ( Figure 1C ). As expected, the 4LCA, which binds the BoNT/A light chain (LC), did not compete with 6A ( Figure 1D ). Furthermore, CR2 did not compete with 3B3 binding ( Figure 1E ), whereas 3B3 did block its own binding ( Figure 1F ). Reciprocal competition studies gave similar results (data not shown). We therefore selected the following mAb combinations for further testing: 2-mAb (4LCA + 6A), 3-mAb (4LCA + 6A + 3B3), and 4-mAb (4LCA + 6A + 3B3 + CR2).
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Having established these quantities for each reagent, we tested the combinations against increasing doses of BoNT/A in vivo (Table 1) . Against 5000 LD50, 2-mAb and 3-mAb both failed to provide 100% neutralization, whereas 4-mAb fully neutralized 5000 LD50 and partially neutralized 7500 LD50 (30%). The addition of the FP increased the potency of all of these combinations. The 2-mAb:FP and 3-mAb:FP complexes neutralized 5000 LD50, and the 3-mAb:FP gave 30% activity against 7500 LD50. 4-mAb:FP achieved 100% neutralization of 40,000 LD50. Notably, the FP had a greater absolute effect on the 4-mAb complex than on the 3-mAb. For example, the 4-mAb:FP provided full survival at a dose of 35,000 LD50 BoNT greater than the maximum dose that enabled We tested these mAb combinations for BoNT/A neutralization in mice, with and without the FP [9, 12] . Complexes were assembled using a step-wise protocol that first bound 6A and 4LCA to BoNT/A, then any additional mAbs, and then the FP. For the 3-mAb and 4-mAb complexes, we biotinylated 3B3, and for the 2-mAb complex, we biotinylated 6A. We then empirically determined by titration the lowest amounts of these components that would afford the 4-mAb:FP complex with 40,000 LD50 in vivo neutralization potency: 20 µg 6A, 20 µg 4LCA, 20 µg 3B3 biotin, 2 µg CR2, and 30 µg FP (data not shown). The lower dose of CR2 was enabled because of its extremely high potency (200 LD50 BoNT/A neutralization by 50 µg in vivo; Dr. Jianlong Lou and Dr. James Marks, personal communication).
Having established these quantities for each reagent, we tested the combinations against increasing doses of BoNT/A in vivo (Table 1) . Against 5000 LD50, 2-mAb and 3-mAb both failed to provide 100% neutralization, whereas 4-mAb fully neutralized 5000 LD50 and partially neutralized 7500 LD50 (30%). The addition of the FP increased the potency of all of these combinations. The 2-mAb:FP and 3-mAb:FP complexes neutralized 5000 LD50, and the 3-mAb:FP gave 30% activity against 7500 LD50. 4-mAb:FP achieved 100% neutralization of 40,000 LD50. Notably, the FP had a greater absolute effect on the 4-mAb complex than on the 3-mAb. For example, the 4-mAb:FP provided full survival at a dose of 35,000 LD50 BoNT greater than the maximum dose that enabled full survival with the 4-mAb alone (e.g., 40 ,000 LD50 vs. 5000 LD50). Thus, the in vivo neutralization potency correlated with the number of mAbs in the complex, and this benefit was further enhanced by the FP. We next assessed the interaction of the 3-mAb:FP and 4-mAb complexes with RBCs in vitro and in vivo. We assembled the complexes in vitro with 200 ng RI-BoNT/A (40,000 LD50 equivalent) then incubated them for 1 h at room temperature with murine RBCs. We washed the RBCs and measured bound complex by flow cytometry with an APC anti-human IgG secondary mAb ( Figure 2 ). Both the 3-mAb:FP and 4-mAb:FP complexes uniformly labeled the RBCs with approximately the same fluorescence intensity. We qualitatively compared the amount of RI-BoNT/A in the 3-mAb:FP + RBC binding reaction before and after RBC binding, using an ELISA with rabbit anti-BoNT/A HC50 antiserum [13] . Following RBC binding, the amount of RI-BoNT/A in solution was reduced to below the detection limit of the assay (Figure 3 ). full survival with the 4-mAb alone (e.g., 40,000 LD50 vs. 5000 LD50). Thus, the in vivo neutralization potency correlated with the number of mAbs in the complex, and this benefit was further enhanced by the FP. 
Adherence of the 3-mAb:FP and 4-mAb:FP Complexes to RBCs In Vitro and In Vivo
We next assessed the interaction of the 3-mAb:FP and 4-mAb complexes with RBCs in vitro and in vivo. We assembled the complexes in vitro with 200 ng RI-BoNT/A (40,000 LD50 equivalent) then incubated them for 1 h at room temperature with murine RBCs. We washed the RBCs and measured bound complex by flow cytometry with an APC anti-human IgG secondary mAb ( Figure 2 ). Both the 3-mAb:FP and 4-mAb:FP complexes uniformly labeled the RBCs with approximately the same fluorescence intensity. We qualitatively compared the amount of RI-BoNT/A in the 3-mAb:FP + RBC binding reaction before and after RBC binding, using an ELISA with rabbit anti-BoNT/A HC50 antiserum [13] . Following RBC binding, the amount of RI-BoNT/A in solution was reduced to below the detection limit of the assay (Figure 3 ). Figure 2 , and compared to a bufferonly sample (Blank). Error bars indicate the S.E.M.
In our previous study, we found that conversion of the 6A and 4LCA mAbs into heteropolymers that adhered BoNT/A to the RBC surface enhanced their neutralization potency. However, the HPcontaining BoNT/A complexes remained in the circulation for at least 2 h [8] . This is in contrast to polyclonal antibodies, which can clear toxin from the blood circulation within minutes [5, 14] . We assessed the time course of BoNT/A clearance from the circulation induced by binding to the 4-mAb:FP complex ( Figure 4 ). We bound 200 ng BoNT/A to the 4-mAb:FP in vitro, injected the complex intravenously into Swiss Webster mice, and obtained blood samples at the following timepoints: 5, 20, 40, 80, 160 and 240 min. Five mice were tested in each group. We assessed RBC binding of the complex to the RBCs using an APC anti-human IgG and flow cytometry. To measure an estimated zero timepoint value, assuming even distribution of the labeled complexes in vivo, prior to clearance, we also mixed the same BoNT/A complex with RBCs from 1.5 mL blood (one mouse equivalent) in vitro.
By the first in vivo timepoint tested, the mean fluorescence intensity (MFI) was 425 ( Figure 4a ,b), compared to 1150 at the estimated zero timepoint sample (in Figure 4b , the zero timepoint is shown in light blue). Labeling declined slowly thereafter, such that binding was still evident 4 h after injection of the complex, with an MFI of 110 (approximately 10% of the estimated labeling at time zero). This suggests that the complexes were cleared in a bi-phasic process. It is also notable that shapes of the curves did not change significantly between 5 and 240 min. We analyzed free BoNT/A in the plasma of these mice ( Figure 5 ). Clearance of free BoNT/A followed a different time course, declining by less than half between the 5 and 20 min timepoints, suggesting that they represented a subset of the immune complexes that were defective in RBC binding and therefore cleared by a different mechanism. In our previous study, we found that conversion of the 6A and 4LCA mAbs into heteropolymers that adhered BoNT/A to the RBC surface enhanced their neutralization potency. However, the HP-containing BoNT/A complexes remained in the circulation for at least 2 h [8] . This is in contrast to polyclonal antibodies, which can clear toxin from the blood circulation within minutes [5, 14] . We assessed the time course of BoNT/A clearance from the circulation induced by binding to the 4-mAb:FP complex ( Figure 4 ). We bound 200 ng BoNT/A to the 4-mAb:FP in vitro, injected the complex intravenously into Swiss Webster mice, and obtained blood samples at the following timepoints: 5, 20, 40, 80, 160 and 240 min. Five mice were tested in each group. We assessed RBC binding of the complex to the RBCs using an APC anti-human IgG and flow cytometry. To measure an estimated zero timepoint value, assuming even distribution of the labeled complexes in vivo, prior to clearance, we also mixed the same BoNT/A complex with RBCs from 1.5 mL blood (one mouse equivalent) in vitro.
By the first in vivo timepoint tested, the mean fluorescence intensity (MFI) was 425 ( Figure 4a ,b), compared to 1150 at the estimated zero timepoint sample (in Figure 4b , the zero timepoint is shown in light blue). Labeling declined slowly thereafter, such that binding was still evident 4 h after injection of the complex, with an MFI of 110 (approximately 10% of the estimated labeling at time zero). This suggests that the complexes were cleared in a bi-phasic process. It is also notable that shapes of the curves did not change significantly between 5 and 240 min. We analyzed free BoNT/A in the plasma of these mice ( Figure 5 ). Clearance of free BoNT/A followed a different time course, declining by less than half between the 5 and 20 min timepoints, suggesting that they represented a subset of the immune complexes that were defective in RBC binding and therefore cleared by a different mechanism. In our previous study, we found that conversion of the 6A and 4LCA mAbs into heteropolymers that adhered BoNT/A to the RBC surface enhanced their neutralization potency. However, the HPcontaining BoNT/A complexes remained in the circulation for at least 2 h [8] . This is in contrast to polyclonal antibodies, which can clear toxin from the blood circulation within minutes [5, 14] . We assessed the time course of BoNT/A clearance from the circulation induced by binding to the 4-mAb:FP complex (Figure 4 ). We bound 200 ng BoNT/A to the 4-mAb:FP in vitro, injected the complex intravenously into Swiss Webster mice, and obtained blood samples at the following timepoints: 5, 20, 40, 80, 160 and 240 min. Five mice were tested in each group. We assessed RBC binding of the complex to the RBCs using an APC anti-human IgG and flow cytometry. To measure an estimated zero timepoint value, assuming even distribution of the labeled complexes in vivo, prior to clearance, we also mixed the same BoNT/A complex with RBCs from 1.5 mL blood (one mouse equivalent) in vitro.
By the first in vivo timepoint tested, the mean fluorescence intensity (MFI) was 425 (Figure 4a ,b), compared to 1150 at the estimated zero timepoint sample (in Figure 4b , the zero timepoint is shown in light blue). Labeling declined slowly thereafter, such that binding was still evident 4 h after injection of the complex, with an MFI of 110 (approximately 10% of the estimated labeling at time zero). This suggests that the complexes were cleared in a bi-phasic process. It is also notable that shapes of the curves did not change significantly between 5 and 240 min. We analyzed free BoNT/A in the plasma of these mice ( Figure 5 ). Clearance of free BoNT/A followed a different time course, declining by less than half between the 5 and 20 min timepoints, suggesting that they represented a subset of the immune complexes that were defective in RBC binding and therefore cleared by a different mechanism. 
Macrophage Uptake of mAb:FP Complexes In Vitro
BoNT immune complexes in the bloodstream are cleared primarily by the liver, where they are taken up by Kupffer cells through Fc receptor-dependent mechanisms [3, 15] . Kupffer cells share essential features with peritoneal macrophages, including expression of Fc receptors and Toll-like receptors, the ability to internalize immune complexes and present antigens, and the ability to polarize into diverse activation states [16] . Our previous study of HPs interacting with peritoneal macrophages showed that increasing the number of Fc domains (4 vs. 3 or 2) improved RI-BoNT/A uptake, and this observation correlated with neutralization potency in vivo [8] . Here, we tested the 3-mAb and 4-mAb combinations, with and without FP, for their ability to facilitate macrophage uptake of an Alexa 488-labeled RI-BoNT/A. We also tested the 4-mAb:FP in combination with RBCs. We assembled the complexes in vitro and incubated them with murine peritoneal macrophages for 30 min, then fixed and mounted the cells and analyzed them by confocal microscopy ( Figure 6 ). In addition, we measured mean Corrected Total Cell Fluorescence (CTCF) using the Zeiss AIM 4.2 SP1 software with IMAGEj ( Figure 7 ). RI-BoNT/A, alone or bound to the 3-mAb or 3-mAb:FP complexes, 
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Discussion
Studies of the protective efficacy of mAbs against diverse toxins have established the general principle that combinations of mAbs generally provide better in vivo protection than individual mAbs [20, 21] . Oligoclonal mAbs can provide some of the benefits of the authentic polyclonal antitoxin antibody response, including enhanced inhibition of toxin activity, improved binding affinity, alteration of toxin conformation, and improved clearance in vivo [22] [23] [24] [25] . However, the creation of protective mAb combinations for use as therapeutics is challenged by the observation that the majority of anti-toxin mAbs described have no intrinsic neutralizing activity [26] , and that mAb combinations do not predictably improve neutralization in vivo relative to single mAbs [23, 24] . Therefore, methods to enhance the sequestration and/or clearance of toxins in vivo may have general utility in improving the efficacy of oligoclonal mAb anti-toxins.
The study of BoNT neutralization by mAbs offers a general paradigm for neutralization of toxins, especially those that pass through the blood circulation during the intoxication process, such as Shiga toxins, staphylococcal enterotoxins, ricin, and anthrax toxin [27] [28] [29] [30] . To use mAbs as a countermeasure for BoNT intoxication, we need to address three fundamental issues. First, BoNT exists in at least seven different serotypes [31] . Second, three or more mAbs need to bind BoNT 
Studies of the protective efficacy of mAbs against diverse toxins have established the general principle that combinations of mAbs generally provide better in vivo protection than individual mAbs [20, 21] . Oligoclonal mAbs can provide some of the benefits of the authentic polyclonal anti-toxin antibody response, including enhanced inhibition of toxin activity, improved binding affinity, alteration of toxin conformation, and improved clearance in vivo [22] [23] [24] [25] . However, the creation of protective mAb combinations for use as therapeutics is challenged by the observation that the majority of anti-toxin mAbs described have no intrinsic neutralizing activity [26] , and that mAb combinations do not predictably improve neutralization in vivo relative to single mAbs [23, 24] . Therefore, methods to enhance the sequestration and/or clearance of toxins in vivo may have general utility in improving the efficacy of oligoclonal mAb anti-toxins.
The study of BoNT neutralization by mAbs offers a general paradigm for neutralization of toxins, especially those that pass through the blood circulation during the intoxication process, such as Shiga toxins, staphylococcal enterotoxins, ricin, and anthrax toxin [27] [28] [29] [30] . To use mAbs as a countermeasure for BoNT intoxication, we need to address three fundamental issues. First, BoNT exists in at least seven different serotypes [31] . Second, three or more mAbs need to bind BoNT simultaneously in order to obtain therapeutic neutralization efficacy in vivo [4, 5] . Third, mAbs that bind to multiple serotypes generally do not have substantial neutralization potency [32] . These factors complicate efforts to create a comprehensive panel of anti-BoNT mAbs, so mAb-based BoNT countermeasures need to inhibit as many parts of the intoxication process as possible [2] . Here, we have continued our studies of how RBC adherence may improve the in vivo BoNT neutralizing capacity of mAb combinations.
We identified a combination of 4 mAbs that work with the FP to give a high level of in vitro neutralization. We then studied subsets of that combination to identify factors that contribute to BoNT neutralization in vivo. When administered without the FP, the neutralization potency increased with the number of mAbs in the complex (2-mAb vs. 3-mAb vs. . This result correlated with the finding that macrophages took up the 4-mAb complex better than the 3-mAb complex. The addition of the FP increased the neutralization potency of each combination, but it had its greatest effect when 4 mAbs were present. In the macrophage uptake experiments, the FP by itself did not increase complex uptake. However, in the presence of RBCs, macrophage uptake of the 4-mAb complex was doubled. This phenomenon reflects the known ability of RBCs to accelerate the transfer of complement-bound immune complexes to macrophages and may explain some of improvement provided by the FP in vivo [33] .
The rapid clearance of the immune complexes from the RBC surface in vivo correlated with previous observations with polyclonal antisera, and was consistent with the speed with which macrophages can engage and phagocytose immune complexes presented by RBCs [3, 34] . More than half of the injected BoNT/A was cleared from the blood circulation by the time the first in vivo timepoint could be assessed, and complexes may have been cleared by RBC-adherent or RBC-independent processes. It is unlikely that the initial drop in BoNT/A in the circulation related to tissue distribution, as has been observed with BoNT/A administered alone, because this process has a half-life of~60 min. It is also possible that some of the BoNT/A immune complexes were cleared without RBC binding, but the substantial improvement in neutralization provided by the FP suggests that RBC binding did occur in vivo.
In our previous studies of mAbs in the heterodimeric HP format, we found that two HPs, which contributed a total of 4 Fc domains to the complex, were taken up more rapidly by macrophages than an HP and a single mAb (3 Fc domains), and that this correlated with neutralization potency in vivo [8] . These findings and the present study are consistent with a model for Fc-receptor dependent IgG uptake in which a threshold level of receptor engagement is required to induce a phagocytic response of the FP-bound complexes [35, 36] . This all-or-nothing response is directly related to IgG density-dependent activation of intracellular signaling pathways, enhanced by a beneficial display of the immune complexes on the RBC surface [33] . Previous studies of BoNT-neutralizing mAbs have shown that 3 mAbs can be sufficient for high level neutralization in vivo [4] , but all of the mAbs studied in Nowakowski et al. bound to the BoNT/A HC domain, which may have placed them in an optimum geometry for macrophage uptake. It is possible that the orientation of Fc domains in an immune complex may affect the ease with which they collaboratively induce Fc receptor cross-linking on the macrophage surface.
The shape of the flow cytometry curves in this experiment revealed a broad heterogeneity of labeling that included a substantial proportion of completely unlabeled RBCs. This may have resulted from incomplete mixing during injection. Alternatively, these shapes would also be consistent with a model in which multiple BoNT immune complexes are removed from the RBCs simultaneously during the short period of time in which the density of the immune complexes on the RBC surface are sufficient to trigger phagocytosis. The level of complex clearance would therefore be a stochastic process determined by extent of macrophage engagement of the RBC membrane during the phagocytic process [37] .
After the initial rapid phase of BoNT/A immune complex clearance, the remaining complexes appeared to stabilize on the RBC surfaces, as they remained bound for many hours and the flow cytometry tracings did not re-distribute into bell-curve shapes. This is consistent with the observation that BoNT/A in the plasma was below the limit of detection by 80 min, i.e., essentially entirely adherent to the RBCs. In addition, their existence on the RBC surface for so long, in comparison to capability of macrophages to rapidly take up complexes in vitro and remove them from the plasma in vivo [34] suggests that the complexes in the second clearance phase were in a configuration that could not be taken up by macrophages. Our provisional model is that the concentration and/or RBC binding density are sufficient for efficient macrophage uptake in the first phase of clearance, but not in the second.
Although the FP by itself did not improve the uptake of the 3-mAb and 4-mAb complexes by the peritoneal macrophages, it did contribute to macrophage activation, as measured by induced TNF-α and IL-10 expression. Notably, the FP and the 4-mAb complex had a strong synergistic effect on IL-10 expression. No comparable synergy was seen with TNF-α expression, indicating that the addition of the FP to the 4-mAb:BoNT/A complex induced M2 polarization of the peritoneal macrophages. Macrophages can take up immune complexes without activation, but they may undergo M2 polarization in the presence of high density IgG complexes and Toll-like receptor (TLR) activation. Notably, M2 polarization is typical of the liver macrophages that are likely to be determinants of BoNT clearance in vivo. Liver macrophages are subject to continuous TLR4 activation from endotoxin, which combines with immune complex stimulation to promote a non-inflammatory, tolerogenic phenotype [38] . In the present study, it is possible that the streptavidin moiety in the FP may have provided a TLR-activating effect to trigger macrophage polarization in the presence of the larger immune complex, as it did not increase the levels of endotoxin present in the macrophage supernatants (data not shown).
The improvement in BoNT/A neutralization provided by the FP likely results from the combined effects of sequestration of BoNT/A on the RBC surface as well as improved complex clearance in the immediate post-exposure period. Although the effect of the FP on macrophage activation was substantial, it did not correlate with improved uptake by macrophages. The benefits of immediate toxin sequestration and improved toxin clearance provided by the FP are countered by the fact that some BoNT/A remained on the RBC surface for many hours. In the present series of experiments, this was balanced by the use of mAbs with high intrinsic BoNT neutralizing activity.
Because mice do not express an RBC complement receptor protein, instead using a platelet-expressed protein for immune adherence, we have been able to somewhat isolate the effects of FP-mediated RBC binding on BoNT neutralization. Nonetheless, a caveat of the present study is that non-RBC-mediated clearance from the blood circulation may have proceeded in parallel to FP-mediated clearance. Additional studies will need to assess how enhanced RBC adherence would be best optimized in for humans, in whom macrophage uptake is a collaboration between Fc receptor interactions and adhesive contributions provided by the complement receptor [39] .
Conclusions
•
Botulinum toxin neutralization in vivo by IgG immune complexes can be improved by fusion protein-mediated adherence to red blood cells (RBCs).
• RBC adherence, mediated by complex binding to a fusion protein (FP), which is a fusion between streptavidin and an anti-glycophorin A scFv, sequesters botulinum neurotoxin from the neuromuscular junction.
• Botulinum toxin-containing immune complexes that have adhered to RBCs through the FP show increased uptake by macrophages and induce M2 macrophage polarization.
Clearance of immune complexes bound to RBCs through an FP shows bi-phasic kinetics, with most clearance occurring within the first five minutes, and the rest declining slowly thereafter.
Materials and Methods
Botulinum Neurotoxin, Fusion Protein, Monoclonal Antibodies and Immune Complex Assembly
Pure Type A1 botulinum neurotoxin (BoNT/A) was obtained from Metabiologics (Madison, WI, USA). We performed all of the experiments with a single lot of toxin, which we assayed for its neurotoxin content using the mouse protection assay, and measured the single LD50 to be 5 pg [12] . The BoNT/A stock was distributed into working aliquots and stored at −20 • C. Purified rabbit anti-BoNT/A polyclonal IgG and recombinant inactive BoNT/A (RI-BoNT/A) were gifts from Inventox, Inc. (Santa Fe, NM, USA) [40, 41] . The 6A and 3B3 human mAbs, which bind the BoNT/A heavy chain (HC), and the 4LCA mAb, which binds the BoNT/A light chain (LC), were previously described [9, 42] . The CR2 mAb, specific for the N-terminal domain of the BoNT/A heavy chain [10] , was obtained from Dr. Jianlong Lou and Dr. James Marks (University of California, San Francisco, CA, USA). The Fusion Protein (FP) was produced in E. coli expression as described previously [9] .
Animals and BoNT/A Neutralization Testing
Female 6-8 week-old Swiss Webster mice were purchased form Taconic Biosciences (Germantown, NY, USA) and housed at the AAALAC-certified animal facility at the Lankenau Institute for Medical Research. All the mice had free access to food and water. All procedures were approved by Lankenau Institute for Medical Research Animal Care (Protocol No: A08-2692, Approval Period: 28 July 2016-27 July 2017) and Use Committee IACUC. For in vivo testing of BoNT/A neutralization, mice were sedated with isoflurane prior to intravenous injection with the mAb and mAb:FP combinations. Mice were monitored hourly for 6 h post-injection, and then twice daily for up to seven days. Mice exhibiting signs of BoNT/A intoxication, such as paralysis, cachexia, hunched backs, eye secretions, rapid breathing, or hypokinesis were euthanized by CO 2 inhalation.
Monoclonal Antibody Competitive Binding Studies
Black Nunc Maxisorp plates (Nalgene Nunc International, Rochester, NY, USA) were coated overnight with 5 µg/mL 4LCA ( Figure 1A-D) or rabbit anti-BoNT/A HC50 antiserum in phosphate buffer saline (PBS) followed by three washes in PBS containing 0.05% Tween 20 (PBST). The plates were blocked with 2% non-fat milk in PBST for 1 h at 37 • C, followed by three PBST washes, and then serial dilutions of RI-BoNT/A in plasma (50 µL each), incubated for 1 h at 37 • C, followed by a 3× PBST wash. Either PBS or 5 µg/mL of the biotinylated mAb (6A or 3B3), diluted in PBS, were added to the samples, incubated for 1 h at 37 • C, and washed 3× in PBST. Streptavidin-poly-horseradish peroxidase conjugate (Thermo Fisher Scientific, Waltham, MA, USA) was added (1:2000) , incubated for 1 h at 37 • C, and washed 3× with PBST. Super Signal ELISA Femto Substrate (Thermo Fisher Scientific, Waltham, MA, USA) was used for detection and relative luminescence values were measured using Biotek Synergy II Microplate reader (BioTek Instruments, Winooski, VT, USA). Excel was used to process the data. MAbs were biotinylated using the EZ-Link™ Hydrazide-Biotin kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Protein concentration was measured using the NanoDrop 1000 (Thermo Fisher Scientific, Waltham, MA, USA).
Immune Complex Assembly and RBC Binding In Vitro and In Vivo
To assemble the FP + mAb containing immune complexes, we used a sequential binding protocol. We incubated the specified dose of BoNT/A or RI-BoNT/A with 20 µg 4LCA and 20 µg 6A for 1 h at room temperature. This was followed by 10 µg 3B3 and 2 µg CR2 mAbs (if needed), another hour of incubation, then 30 µg FP (if indicated), followed by another 30 min incubation. For the in vitro RBC binding experiments, Swiss Webster mouse blood (1.5 mL) was collected in heparinized tubes and centrifuged for 20 min at 8000 RPM, and the RBC pellet was washed 3× in 1000 µL PBS:1% BSA. The pellet was resuspended in 3600 µL PBS-BSA, divided into three aliquots, and rocked gently at room temperature until use. RBCs were gently rocked with the indicated complexes for 1 h, centrifuged
